---
title: "Dynavax Tech | 10-Q: FY2025 Q1 Revenue Misses Estimate at USD 68.16 M"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/238981026.md"
datetime: "2025-05-06T20:18:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/238981026.md)
  - [en](https://longbridge.com/en/news/238981026.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/238981026.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/238981026.md) | [繁體中文](https://longbridge.com/zh-HK/news/238981026.md)


# Dynavax Tech | 10-Q: FY2025 Q1 Revenue Misses Estimate at USD 68.16 M

Revenue: As of FY2025 Q1, the actual value is USD 68.16 M, missing the estimate of USD 68.39 M.

EPS: As of FY2025 Q1, the actual value is USD -0.77.

EBIT: As of FY2025 Q1, the actual value is USD -97.88 M.

### Segment Revenue

-   **Product Revenue, Net**: $64.959 million for the three months ended March 31, 2025, compared to $47.845 million for the same period in 2024, representing a 36% increase.
-   **Other Revenue**: $3.205 million for the three months ended March 31, 2025, compared to $2.945 million for the same period in 2024, representing a 9% increase.

### Operational Metrics

-   **Net Loss**: - $96.099 million for the three months ended March 31, 2025, compared to - $8.721 million for the same period in 2024.
-   **Loss from Operations**: - $23.630 million for the three months ended March 31, 2025, compared to - $17.769 million for the same period in 2024.
-   **Total Operating Expenses**: $91.794 million for the three months ended March 31, 2025, compared to $68.559 million for the same period in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: - $19.639 million for the three months ended March 31, 2025, compared to - $16.679 million for the same period in 2024.
-   **Net Cash Provided by Investing Activities**: $6.910 million for the three months ended March 31, 2025, compared to $2.831 million for the same period in 2024.
-   **Net Cash Used in Financing Activities**: - $31.882 million for the three months ended March 31, 2025, compared to - $4.203 million for the same period in 2024.

### Unique Metrics

-   **Allowance for Doubtful Accounts**: Approximately $11.0 million recorded during the three months ended March 31, 2025, related to the contract asset recognized for Clover.

### Future Outlook and Strategy

-   **Core Business Focus**: Dynavax Technologies Corporation plans to advance its clinical pipeline leveraging CpG 1018 adjuvant, including a Phase 1⁄2 clinical trial for shingles and additional clinical and manufacturing activities for plague, fully funded by the U.S. Department of Defense.
-   **Non-Core Business**: The company is pursuing collection of $71.3 million due from Clover, with $60.3 million payable to CEPI upon occurrence of applicable payment trigger events.
-   **Priority**: The company anticipates that its cash and cash equivalents, and short-term marketable securities as of March 31, 2025, and anticipated revenues from HEPLISAV-B will be sufficient to fund operations for at least the next 12 months.

### 相关股票

- [Dynavax Tech (DVAX.US)](https://longbridge.com/zh-CN/quote/DVAX.US.md)

## 相关资讯与研究

- [Dynavox Group CFO to Step Down in Planned Transition by January 2027](https://longbridge.com/zh-CN/news/279902984.md)
- [Dynavox Q4 revenue rises 16% to SEK 677 million](https://longbridge.com/zh-CN/news/274923640.md)
- [Gold Hunter shifts from quiet buildup to fully funded drilling push at Newfoundland gold district](https://longbridge.com/zh-CN/news/281261616.md)
- [Warren Buffett Admits He Sold Apple Too Early, Eyes Future Buying But Not Yet](https://longbridge.com/zh-CN/news/281336451.md)
- [Warren Buffett teams up with NBA superstar Stephen Curry for charity lunch, reviving iconic auction](https://longbridge.com/zh-CN/news/281182480.md)